+Compare
NVAX
Stock ticker:
NASDAQ
AS OF
Jul 1 closing price
Price
$57.15
Change
+$5.72 (+11.12%)
Capitalization
4.02B

NVAX Price Prediction, Novavax AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Jun 06, 2022

Momentum Indicator for NVAX turns negative, indicating new downward trend

NVAX saw its Momentum Indicator move below the 0 level on June 03, 2022. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In 75 of the 88 cases, the stock moved further down in the following days. The odds of a decline are at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis
Bullish Trend Analysis

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NVAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (68.493) is normal, around the industry mean (24.351). P/E Ratio (0.000) is within average values for comparable stocks, (94.483). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.898). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (2.491) is also within normal values, averaging (309.271).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

NVAX is expected to report earnings to rise 108.20% to $5.33 per share on August 05

Novavax NVAX Stock Earnings Reports
Q2'22
Est.
$5.33
Q1'22
Missed
by $0.13
Q4'21
Missed
by $9.38
Q3'21
Missed
by $0.40
Q2'21
Missed
by $1.12
The last earnings report on May 09 showed earnings per share of $2.56, missing the estimate of $2.69. With 6.42M shares outstanding, the current market capitalization sits at 4.02B.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Global Blood Therapeutics (NASDAQ:GBT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.72B. The market cap for tickers in the group ranges from 2.5K to 250.31B. NONOF holds the highest valuation in this group at 250.31B. The lowest valued company is IMUND at 2.5K.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -0%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was -36%. EVFM experienced the highest price growth at 145%, while PCNTD experienced the biggest fall at -81%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -76%. For the same stocks of the Industry, the average monthly volume growth was -46% and the average quarterly volume growth was -63%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 61
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: -17 (-100 ... +100)
AI

View a ticker or compare two or three

AI
A.I. Advisor
published General Information

General Information

a company which engages in development of novel recombinant vaccines

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
21 Firstfield Road
Phone
+1 240 268-2000
Employees
1541
Web
https://www.novavax.com

Interesting Tickers

1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ONEV99.201.22
+1.25%
SPDR® Russell 1000 Low Vol Foc ETF
DFAS48.510.51
+1.06%
Dimensional US Small Cap ETF
DAUG32.340.01
+0.04%
FT Cboe Vest US Equity Deep Bfr ETF Aug
REW22.14-0.05
-0.23%
ProShares UltraShort Technology
QYLG23.88-0.06
-0.25%
Global X Nasdaq 100® Covered Call&Gr ETF

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with GLUE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then GLUE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
+11.12%
GLUE - NVAX
48%
Loosely correlated
+4.55%
DNA - NVAX
44%
Loosely correlated
+0.42%
GRPH - NVAX
33%
Loosely correlated
+2.55%
ADCT - NVAX
33%
Poorly correlated
+6.92%
HGEN - NVAX
32%
Poorly correlated
-7.34%
More